Trials / Completed

CompletedNCT00096980

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 300 (planned)

Sponsor: Genentech, Inc. · Industry
Sex: All
Age: 18 Years – 70 Years
Healthy volunteers: Not accepted

Summary

This study is an open label, randomized, multicenter study designed to compare the efficacy of 12 weeks of subcutaneously administered efalizumab (monotherapy) with that of combination therapy (Efalizumab and a topical corticosteroid ointment) in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy. The study will also evaluate the safety and tolerability of 30 months of continuous efalizumab treatment in those subjects who derive benefit from the initial 12 weeks of treatment.

Conditions

Psoriasis

Interventions

Type	Name	Description
DRUG	Raptiva (efalizumab)

Timeline

Start date: 2001-02-01
Completion: 2004-05-01
First posted: 2004-11-18
Last updated: 2013-06-21

Source: ClinicalTrials.gov record NCT00096980. Inclusion in this directory is not an endorsement.